Literature DB >> 15958679

Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara.

Caroline Staib1, Sigrid Kisling1, Volker Erfle1, Gerd Sutter2,1.   

Abstract

Interleukin 1 (IL1) is an important regulator of inflammatory responses and contributes to host immune defence against infection. Vaccinia virus encodes a viral soluble IL1beta receptor (IL1betaR), which modulates the acute-phase host response to infection and might influence the induction of immune responses against virus-associated antigens. Here, modified vaccinia virus Ankara (MVA) mutants defective in IL1betaR production were produced by insertion of selectable marker gene sequences that precisely deleted the IL1betaR coding sequences from the MVA genome (MVA-DeltaIL1betaR). Analysis of MVA mutants indicated that deletion of the IL1betaR gene did not abrogate the formation of MVA progeny upon tissue culture propagation. After high-dose intranasal infection with MVA-DeltaIL1betaR, mice showed no signs of fever or other illness, suggesting that the avirulent phenotype remained preserved for MVA-DeltaIL1betaR. Following vaccination of mice, MVA-DeltaIL1betaR or non-mutated MVA induced similar acute-phase immune responses. Importantly, when monitored at the memory phase, significantly higher vaccinia virus-specific total CD8(+) and HLA-A*0201-binding peptide epitope-specific T-cell responses were found after vaccination of HLA-A*0201-transgenic and non-transgenic mice with MVA-DeltaIL1betaR. Moreover, 4-6 months after vaccination, MVA-DeltaIL1betaR provided higher levels of protection against lethal respiratory challenge infection with virulent vaccinia virus strain Western Reserve compared with wild-type MVA. These data suggest that deletion of the viral IL1betaR gene may be considered a relevant approach to amplify the virus-specific CD8+ memory T-cell response and duration of protective immunity obtained after MVA vaccination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15958679     DOI: 10.1099/vir.0.80646-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  45 in total

1.  Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Authors:  Karen Baur; Kay Brinkmann; Marc Schweneker; Juliane Pätzold; Christine Meisinger-Henschel; Judith Hermann; Robin Steigerwald; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

Review 2.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 3.  Viruses as vaccine vectors for infectious diseases and cancer.

Authors:  Simon J Draper; Jonathan L Heeney
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

Review 4.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

5.  Diversity in the acute CD8 T cell response to vaccinia virus in humans.

Authors:  Lichen Jing; Tiana M Chong; Christopher L McClurkan; Jay Huang; Brian T Story; David M Koelle
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

6.  Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques.

Authors:  David A Garber; Leigh A O'Mara; Sailaja Gangadhara; Monica McQuoid; Xiugen Zhang; Rui Zheng; Kiran Gill; Meena Verma; Tianwei Yu; Brent Johnson; Bing Li; Cynthia A Derdeyn; Chris Ibegbu; John D Altman; Eric Hunter; Mark B Feinberg
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

7.  Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.

Authors:  Juan García-Arriaza; José Luis Nájera; Carmen E Gómez; Carlos Oscar S Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-08-24       Impact factor: 3.240

8.  The orthopoxvirus 68-kilodalton ankyrin-like protein is essential for DNA replication and complete gene expression of modified vaccinia virus Ankara in nonpermissive human and murine cells.

Authors:  Karin M Sperling; Astrid Schwantes; Caroline Staib; Barbara S Schnierle; Gerd Sutter
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

9.  Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk.

Authors:  Genevieve G A Fouda; Joshua D Amos; Andrew B Wilks; Justin Pollara; Caroline A Ray; Anjali Chand; Erika L Kunz; Brooke E Liebl; Kaylan Whitaker; Angela Carville; Shannon Smith; Lisa Colvin; David J Pickup; Herman F Staats; Glenn Overman; Krissey Eutsey-Lloyd; Robert Parks; Haiyan Chen; Celia Labranche; Susan Barnett; Georgia D Tomaras; Guido Ferrari; David C Montefiori; Hua-Xin Liao; Norman L Letvin; Barton F Haynes; Sallie R Permar
Journal:  J Virol       Date:  2013-04-17       Impact factor: 5.103

10.  Camelpox virus encodes a schlafen-like protein that affects orthopoxvirus virulence.

Authors:  Caroline Gubser; Rory Goodbody; Andrea Ecker; Gareth Brady; Luke A J O'Neill; Nathalie Jacobs; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2007-06       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.